vs
Side-by-side financial comparison of Orange County Bancorp, Inc. (OBT) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Orange County Bancorp, Inc. is the larger business by last-quarter revenue ($33.0M vs $20.4M, roughly 1.6× Sight Sciences, Inc.). Orange County Bancorp, Inc. runs the higher net margin — 37.6% vs -20.4%, a 58.0% gap on every dollar of revenue. On growth, Orange County Bancorp, Inc. posted the faster year-over-year revenue change (20.6% vs 6.9%). Orange County Bancorp, Inc. produced more free cash flow last quarter ($41.3M vs $-2.0M). Over the past eight quarters, Orange County Bancorp, Inc.'s revenue compounded faster (14.3% CAGR vs 2.9%).
Orange County Bancorp, Inc. is a Delaware-registered bank holding company operating mainly in New York, U.S. It offers a full range of retail and commercial banking services, including deposit accounts, loans and wealth management solutions, serving individual consumers, small and mid-sized corporate clients in its regional footprint.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
OBT vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $33.0M | $20.4M |
| Net Profit | $12.4M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | 41.4% | -18.0% |
| Net Margin | 37.6% | -20.4% |
| Revenue YoY | 20.6% | 6.9% |
| Net Profit YoY | 73.5% | 64.9% |
| EPS (diluted) | $0.94 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $33.0M | $20.4M | ||
| Q3 25 | $33.7M | $19.9M | ||
| Q2 25 | $32.5M | $19.6M | ||
| Q1 25 | $28.0M | $17.5M | ||
| Q4 24 | $27.4M | $19.1M | ||
| Q3 24 | $27.1M | $20.2M | ||
| Q2 24 | $27.9M | $21.4M | ||
| Q1 24 | $25.3M | $19.3M |
| Q4 25 | $12.4M | $-4.2M | ||
| Q3 25 | $10.0M | $-8.2M | ||
| Q2 25 | $10.5M | $-11.9M | ||
| Q1 25 | $8.7M | $-14.2M | ||
| Q4 24 | $7.2M | $-11.8M | ||
| Q3 24 | $3.2M | $-11.1M | ||
| Q2 24 | $8.2M | $-12.3M | ||
| Q1 24 | $9.3M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | 41.4% | -18.0% | ||
| Q3 25 | 38.6% | -39.7% | ||
| Q2 25 | 41.9% | -59.6% | ||
| Q1 25 | 40.3% | -79.2% | ||
| Q4 24 | 32.8% | -62.5% | ||
| Q3 24 | 14.8% | -55.7% | ||
| Q2 24 | 36.6% | -59.2% | ||
| Q1 24 | 45.9% | -76.4% |
| Q4 25 | 37.6% | -20.4% | ||
| Q3 25 | 29.7% | -41.0% | ||
| Q2 25 | 32.2% | -61.0% | ||
| Q1 25 | 31.1% | -80.8% | ||
| Q4 24 | 26.2% | -62.1% | ||
| Q3 24 | 11.8% | -54.9% | ||
| Q2 24 | 29.4% | -57.7% | ||
| Q1 24 | 36.7% | -84.4% |
| Q4 25 | $0.94 | $-0.07 | ||
| Q3 25 | $0.75 | $-0.16 | ||
| Q2 25 | $0.87 | $-0.23 | ||
| Q1 25 | $0.77 | $-0.28 | ||
| Q4 24 | $0.64 | $-0.23 | ||
| Q3 24 | $0.28 | $-0.22 | ||
| Q2 24 | $0.73 | $-0.25 | ||
| Q1 24 | $0.82 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $284.4M | $63.9M |
| Total Assets | $2.7B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M | ||
| Q1 24 | — | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $284.4M | $63.9M | ||
| Q3 25 | $270.1M | $64.3M | ||
| Q2 25 | $252.6M | $70.0M | ||
| Q1 25 | $201.3M | $77.6M | ||
| Q4 24 | $185.5M | $87.5M | ||
| Q3 24 | $193.1M | $95.0M | ||
| Q2 24 | $177.5M | $101.6M | ||
| Q1 24 | $168.7M | $109.2M |
| Q4 25 | $2.7B | $115.3M | ||
| Q3 25 | $2.6B | $116.3M | ||
| Q2 25 | $2.6B | $122.0M | ||
| Q1 25 | $2.6B | $129.7M | ||
| Q4 24 | $2.5B | $142.8M | ||
| Q3 24 | $2.5B | $143.6M | ||
| Q2 24 | $2.5B | $149.7M | ||
| Q1 24 | $2.5B | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.8M | $-1.8M |
| Free Cash FlowOCF − Capex | $41.3M | $-2.0M |
| FCF MarginFCF / Revenue | 125.1% | -9.7% |
| Capex IntensityCapex / Revenue | 7.6% | 0.8% |
| Cash ConversionOCF / Net Profit | 3.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $69.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.8M | $-1.8M | ||
| Q3 25 | $30.2M | $-8.7M | ||
| Q2 25 | $-5.0M | $-7.5M | ||
| Q1 25 | $4.8M | $-11.6M | ||
| Q4 24 | $34.6M | $-3.5M | ||
| Q3 24 | $10.2M | $362.0K | ||
| Q2 24 | $9.3M | $-9.5M | ||
| Q1 24 | $2.3M | $-9.8M |
| Q4 25 | $41.3M | $-2.0M | ||
| Q3 25 | $29.6M | $-8.9M | ||
| Q2 25 | $-5.7M | $-7.8M | ||
| Q1 25 | $4.3M | — | ||
| Q4 24 | $32.9M | $-3.6M | ||
| Q3 24 | $10.0M | $311.0K | ||
| Q2 24 | $9.2M | $-9.5M | ||
| Q1 24 | $2.0M | $-9.9M |
| Q4 25 | 125.1% | -9.7% | ||
| Q3 25 | 87.8% | -44.7% | ||
| Q2 25 | -17.5% | -39.6% | ||
| Q1 25 | 15.5% | — | ||
| Q4 24 | 120.0% | -18.9% | ||
| Q3 24 | 36.7% | 1.5% | ||
| Q2 24 | 32.8% | -44.7% | ||
| Q1 24 | 7.9% | -51.4% |
| Q4 25 | 7.6% | 0.8% | ||
| Q3 25 | 1.8% | 0.9% | ||
| Q2 25 | 2.3% | 1.1% | ||
| Q1 25 | 1.8% | 0.0% | ||
| Q4 24 | 6.3% | 0.7% | ||
| Q3 24 | 1.1% | 0.3% | ||
| Q2 24 | 0.4% | 0.4% | ||
| Q1 24 | 1.0% | 0.6% |
| Q4 25 | 3.53× | — | ||
| Q3 25 | 3.01× | — | ||
| Q2 25 | -0.47× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 4.83× | — | ||
| Q3 24 | 3.19× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OBT
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
